Culture Biosciences Raises $80 Million Series B

<p><strong>SAN FRANCISCO<&sol;strong> &&num;8212&semi; <a href&equals;"https&colon;&sol;&sol;www&period;culturebiosciences&period;com&sol;" target&equals;"&lowbar;blank" rel&equals;"noopener">Culture Biosciences<&sol;a>&comma; a company enabling biotech firms to develop and scale manufacturing processes in the cloud&comma; announced a Series B financing of &dollar;80 million led by <a href&equals;"http&colon;&sol;&sol;www&period;npv&period;vc&sol;" target&equals;"&lowbar;blank" rel&equals;"noopener">Northpond Ventures<&sol;a>&period; <a href&equals;"https&colon;&sol;&sol;synthesis&period;capital&sol;" target&equals;"&lowbar;blank" rel&equals;"noopener">Synthesis Capital<&sol;a> also participated in the round&period; Existing investors Cultivian Sandbox Ventures&comma; The Production Board&comma; Craft Ventures&comma; E14 Fund&comma; Box Group&comma; Verily Life Sciences&comma; and Section 32 also contributed&period; Andrew Lee&comma; Ph&period;D&period;&comma; of Northpond Ventures will join Culture’s Board of Directors&period;<&sol;p>&NewLine;<p>&&num;8220&semi;Recently there’s been an explosion in the number of new companies in synthetic biology and biopharmaceuticals&comma; and large multinational corporations are also increasingly participating in this space&comma;&&num;8221&semi; said Will Patrick&comma; CEO and co-founder&comma; Culture Biosciences&period; &OpenCurlyDoubleQuote;Although demand for biomanufactured products—from food to clothing to vaccines—is surging&comma; there&&num;8217&semi;s a huge gap in the infrastructure required to produce these bioproducts at commercial scale&period;”<&sol;p>&NewLine;<p>Importantly&comma; there currently isn’t enough manufacturing capacity in the world to support this new wave of synthetic biology products&period; Today’s global capacity falls <a href&equals;"https&colon;&sol;&sol;www&period;bcg&period;com&sol;en-us&sol;publications&sol;2021&sol;the-benefits-of-plant-based-meats" target&equals;"&lowbar;blank" rel&equals;"noopener"><em>100x short<&sol;em><&sol;a> of what would be needed to meet the demand for fermentation-based animal protein in 2030&period; This major gap in large-scale capacity is what Culture is aiming to tackle for its clients looking to scale their processes up to manufacturing&comma; starting with pilot-scale bioreactors&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;Demand for sustainable bio-based products is rapidly increasing&comma; but innovators face two key challenges&comma;” explained Andrew Lee&comma; Ph&period;D&period;&comma; Northpond Ventures&period; &OpenCurlyDoubleQuote;Culture’s cloud bioreactor lab already addresses the first challenge&colon; bench-scale process optimization&period; Companies still need to scale to commercial quantities&comma; however&period; By expanding its technology and data infrastructure&comma; Culture can address this growing market need&period; We’re excited at Northpond to help make that happen&period;”<&sol;p>&NewLine;<p>Since announcing a &dollar;15 million Series A in 2020&comma; Culture has grown 3x year-over-year and invested in scaling out its facilities&comma; offerings&comma; and team&period; Key achievements include&colon;<&sol;p>&NewLine;<ul>&NewLine;<li>Accelerating bioprocess development for 30&plus; of the world’s leading biotech companies<&sol;li>&NewLine;<li>Streamlining data analysis and cross-team collaboration for clients by launching Culture’s Cloud Console&comma; a one-stop web app for experiment data and insights<&sol;li>&NewLine;<li>Launching new capabilities beyond fermentation&comma; such as mammalian cell culture and analytical chemistry<&sol;li>&NewLine;<li>More than doubling full-time employee count in the past year<&sol;li>&NewLine;<&sol;ul>&NewLine;<p>To date&comma; Culture has raised over &dollar;100 million&period; This new round of funding will be used to build and scale 5L and 250L cloud bioreactors&comma; supporting customer demand for larger quantities of material to use for testing and regulatory approval&period; In a survey conducted by the company in 2020&comma; participating biopharma and synthetic biology companies indicated that&comma; out of all potential new product offerings&comma; pilot scale bioreactors would be the most beneficial to their work&period; Now&comma; Culture’s clients can develop&comma; optimize&comma; and scale their bioproducts virtually&period; Many customers are already signing up to use the larger tanks when they become available&period;<&sol;p>&NewLine;

Editor

Wispr Scores $25 Million Series A Extension

SAN FRANCISCO -- Wispr, the voice-to-text AI that turns speech into clear, polished writing in every…

1 day

Numeric Dials Up $51 Million Series B

SAN FRANCISCO -- Numeric, an AI accounting automation platform, has raised a $51 million Series…

1 day

Apple Names 45 Finalists for App Store of the Year Awards

Apple has announced 45 finalists for this year’s App Store Awards, recognizing the best apps…

2 days

UC Reaches Agreement With Nurses, Strike Canceled

The University of California (UC) and the California Nurses Association (CNA) have reached a tentative…

4 days

HouseRX Rakes In $55 Million Series B

SAN FRANCISCO -- House Rx, a health tech company focused on making specialty medications more accessible and…

4 days

King Charles Honors NVIDIA’s Jensen Huang

Britain's King has given an award to the King of NVIDIA! NVIDIA founder and CEO…

4 days